Thymosin Alpha-1

What is Thymosin Alpha-1?

Thymosin alpha-1 (Tα1, thymalfasin, brand name Zadaxin) is a synthetic 28-amino-acid peptide originally isolated from calf thymus extract in 1972 by Allan Goldstein and colleagues at Albert Einstein College of Medicine. The synthetic form was characterized in 1977 and entered clinical development in the 1980s. It modulates immune function primarily through dendritic cell, T cell, and natural killer cell activation. The full sequence is acetylated at the N-terminus.

The peptide is one of several biologically active polypeptides found in thymic extract. Unlike crude thymic extracts, which contain variable mixtures of unrelated proteins, synthetic thymosin alpha-1 is a single well-characterized molecule with reproducible pharmacology. This distinction matters because much of the historical thymic-extract literature is not directly translatable to current Zadaxin trials.

The molecule was granted FDA orphan drug designation for hepatitis B in 1991, one of the earliest peptides to receive that classification. China approved Zadaxin for hepatitis B in 1996. The compound has subsequently received marketing authorization in more than 35 countries. EMA centralized authorization was never pursued. The US Phase 3 program in hepatitis C and melanoma did not lead to an NDA filing.

Mechanism of Action

Thymosin alpha-1 does not bind a single named receptor in the way GLP-1 or melanocortin agonists do. It acts as an immunomodulatory signaling molecule that operates on multiple immune cell types simultaneously.

The most consistently documented mechanism is Toll-like receptor 9 (TLR9) signaling. Thymosin alpha-1 binds and modulates TLR9, which is expressed on dendritic cells and B cells. TLR9 activation drives type I interferon production and shifts immune responses toward Th1 (cellular) immunity, which is the relevant arm for viral infections, intracellular pathogens, and tumor surveillance. This mechanism is largely responsible for the hepatitis B effects.

Beyond TLR9, thymosin alpha-1 has been documented to increase T cell maturation in the thymus, restore T cell function in immunosuppressed patients, increase natural killer (NK) cell cytotoxicity, modulate dendritic cell antigen presentation, and balance Th1/Th2 cytokine production. The combined effect is restoration of immune competence in patients with viral infection, sepsis-induced immunoparalysis, or cancer-related immunosuppression.

The pharmacokinetic profile is straightforward. Peak plasma concentration occurs 1 to 2 hours after subcutaneous injection with a half-life of less than 3 hours. The short half-life is offset by the persistence of the downstream immunomodulatory effects, which last days after individual doses.

The Hepatitis B Evidence

The hepatitis B clinical-trial program is the strongest part of the thymosin alpha-1 evidence base. The first placebo-controlled trial was published by Mutchnick et al. in 1991. The optimal 26-week dosing schedule (1.6 mg subcutaneously twice weekly) was established by Chien et al. in 1998. Subsequent meta-analyses of pooled hepatitis B trials reported significant improvements in delayed virological response and combined HBV DNA suppression with seroconversion compared with placebo or no treatment.

The hepatitis B mechanism appears to involve restoring T cell function in chronically infected patients whose immune systems have failed to clear the virus. Unlike interferon-alpha (which produces rapid response but substantial side effects), thymosin alpha-1 produces a delayed response that builds over months and is generally well-tolerated. The two have been compared in head-to-head trials with comparable long-term efficacy and a substantially better safety profile for thymosin alpha-1.

The dosing protocol used for hepatitis B approval is 1.6 mg subcutaneously twice weekly for 26 weeks, with extension to 12 months in partial responders. This is the protocol on the Zadaxin label in approved markets.

Sepsis and Critical Care

Thymosin alpha-1 has been studied in sepsis with mixed results. The most cited trial is a 2013 randomized controlled trial in 361 patients in Chinese ICUs by Wu and colleagues. Patients received either thymosin alpha-1 (1.6 mg every 12 hours for the first 24 hours, then daily for 7 days) or placebo on top of standard sepsis care. The trial reported a reduction in 28-day mortality from 41 percent to 28 percent in the thymosin alpha-1 arm.

The effect size is large for an immunomodulatory adjunct. Replication in non-Chinese populations has been inconsistent. A 2016 systematic review concluded that thymosin alpha-1 produced a statistically significant mortality reduction in pooled analysis, but the heterogeneity across trials limits firm conclusions about which patient subgroups benefit most. The indication is not standard of care in the US or Europe.

The mechanistic rationale is sepsis-induced immunoparalysis. After the initial pro-inflammatory phase of sepsis, surviving patients enter a compensatory anti-inflammatory phase in which T cell function is suppressed and risk of secondary infection rises. Thymosin alpha-1 reactivates T cell function during this phase, which may explain the mortality benefit in trials that enrolled patients during the immunosuppressive period rather than the initial cytokine storm.

Cancer, Long COVID, and Other Indications

Thymosin alpha-1 has been studied in cancer immunotherapy primarily as an adjunct to other treatments rather than monotherapy. A 2009 Phase 2 trial in metastatic melanoma combined thymosin alpha-1 with dacarbazine and interferon, with some signal but not enough to drive registration. Hepatocellular carcinoma trials have shown adjunctive benefit with chemotherapy. The cancer evidence base is positive but does not approach the strength of the hepatitis B data.

A 2024 publication on acute-on-chronic liver failure (ACLF) reported substantial transplant-free survival improvement with thymosin alpha-1, with effects in some endpoints reaching 22 percentage points. This is among the strongest recent findings in the thymosin alpha-1 literature.

Early in the COVID-19 pandemic, Chinese hospitals reported observational use of thymosin alpha-1 in severe disease with apparent mortality reduction. None of these reports met the standard for randomized evidence. Long COVID applications have been proposed but no published RCT has tested the indication.

Approved Label Dose (Hepatitis B)

The Zadaxin label prescribes 1.6 mg administered subcutaneously twice weekly for 26 weeks for chronic hepatitis B. The schedule is identical across the 35-plus countries with marketing authorization. Treatment may be extended to 12 months in patients who show partial virological response at week 26. The 1.6 mg figure was selected through Phase 2 dose-finding that compared lower doses (0.4 to 0.9 mg) and higher doses (3.2 mg). Higher doses did not improve efficacy. Lower doses produced incomplete immune response. Chien and colleagues established this regimen in 1998 through controlled dose-finding work, and it remains the registrational dose in Zadaxin product labeling today across all approved jurisdictions.

Sepsis and Critical Care Dosing

The 2013 Chinese ICU sepsis trial used a different schedule. Patients received 1.6 mg subcutaneously every 12 hours for the first 24 hours, then 1.6 mg once daily for the next 6 days, in addition to standard sepsis care. This accelerated front-load reflects the urgency of sepsis-induced immunoparalysis. T cell function declines within days of the initial cytokine storm. The 28-day mortality reduction (from 41 percent to 28 percent in the active arm) supported this front-loaded protocol for acute critical-care use. Whether this schedule generalizes outside Chinese ICU populations is unsettled, since replication in Western trials has been inconsistent.

Cancer Adjuvant Protocols

Cancer adjuvant studies have used variable dosing depending on the chemotherapy or immunotherapy combination tested. Common schedules include 1.6 mg subcutaneously daily for 5 days per chemotherapy cycle, or 1.6 mg subcutaneously twice weekly throughout the treatment course. The hepatocellular carcinoma adjuvant program has tested both schedules. Melanoma combination work used 1.6 mg subcutaneously twice weekly alongside dacarbazine and interferon. Cancer dosing has not been standardized to a single label-equivalent protocol, because the indications, combination regimens, and treatment durations vary widely across studies.

Pharmacokinetics

Subcutaneous administration produces peak plasma concentration within 1 to 2 hours, with a terminal plasma half-life of less than 3 hours. The short plasma half-life is misleading on its own. Downstream immunomodulatory effects, including TLR9-driven dendritic cell activation and T cell function restoration, persist for days after each dose. This is the pharmacological basis for twice-weekly dosing in hepatitis B and daily dosing in acute sepsis despite the short plasma exposure. The peptide is cleared by standard protein metabolism without renal or hepatic accumulation, which simplifies dosing in patients with comorbidities. No dose adjustment is required for mild to moderate renal or hepatic impairment based on currently published data.

Off-Label Compounded and Research-Chemical Use

Prior to the FDA Category 2 listing in September 2023, thymosin alpha-1 was widely compounded by 503A pharmacies in the US for off-label use in chronic immune dysfunction, Lyme disease, chronic fatigue, and post-viral immune support. Reported off-label protocols typically followed the 1.6 mg twice weekly subcutaneous schedule from the Zadaxin hepatitis B label, with extended cycles of 12 to 24 weeks. Lower-dose protocols using 0.8 to 1.6 mg twice weekly have circulated in functional medicine and integrative settings. Higher-dose protocols (3.2 mg daily) are rare and lack pharmacokinetic justification beyond the original dose-finding work that selected 1.6 mg as optimal. Legal compounding access in the US ended with the September 2023 Category 2 listing. The compound continues to be sold through online research-chemical vendors as a research peptide, and prescription access remains available in the 35-plus countries with Zadaxin marketing authorization. The PCAC reconsideration in July 2026 will determine whether US compounding access reopens.

Safety and Side Effect Profile

The thymosin alpha-1 safety profile is among the cleanest in the clinical-trial peptide class. Across more than 11,000 subjects in published trials, the most common adverse events are:

Injection-site reactions (erythema, mild discomfort) in approximately 5 to 10 percent of subjects. Generally mild and self-limited.

Mild flushing or transient malaise in a smaller percentage, typically within hours of dosing.

No clinically meaningful drug-drug interactions have been documented at the doses used for hepatitis B and immunomodulation.

No serious systemic toxicity has emerged from the post-marketing surveillance covering more than 600,000 treated patients in approved markets.

Theoretical concerns include the same considerations that apply to immune modulators generally. Patients with autoimmune disease may experience disease flares from immune activation, though this has not been documented as a clinically significant problem at therapeutic doses. Transplant recipients on immunosuppression are typically excluded from thymosin alpha-1 use to avoid graft rejection.

Regulatory Status

Outside the United States. Thymosin alpha-1 (Zadaxin, thymalfasin) is approved in more than 35 countries for chronic hepatitis B, hepatitis C, and as an immunomodulatory adjunct. China is the largest market. Italy, Russia, parts of South America, and Asia approved Zadaxin between 1996 and 2010. The compound is widely used in oncology supportive care and critical care in these markets.

United States. Thymosin alpha-1 has never received FDA approval. SciClone conducted US Phase 3 trials in hepatitis C and melanoma but did not complete an NDA submission. The compound was compounded by 503A pharmacies for off-label use in immune dysfunction, chronic Lyme disease, and other indications through the 2000s and 2010s.

In September 2023, the FDA added thymosin alpha-1 to the Category 2 bulks list, prohibiting compounding under Section 503A. The compound is one of those scheduled for reconsideration at the PCAC meeting on July 23 and 24, 2026. The international approval history and large safety database arguably provide more support for Category 1 reclassification than for most other peptides on the list, but the outcome is not predictable.

WADA status. Thymosin alpha-1 does not currently appear on the WADA Prohibited List. The compound is immunomodulatory rather than performance-enhancing in the conventional sense, which differentiates it from thymosin beta-4 (TB-500), which is banned.

Thymosin Alpha-1 vs Other Immune Peptides

Thymosin alpha-1 is structurally and mechanistically distinct from thymosin beta-4 (TB-500). The two share the "thymosin" name but are different molecules with different biology. Thymosin alpha-1 is an immune modulator. Thymosin beta-4 is a tissue-repair peptide that binds actin and supports wound healing. They are not interchangeable.

Compared with other immune-supporting peptides like LL-37 (a cathelicidin antimicrobial peptide) or KPV (an alpha-MSH-derived anti-inflammatory tripeptide), thymosin alpha-1 has the largest clinical-trial evidence base by orders of magnitude. LL-37 and KPV have research interest but no comparable Phase 3 program.

In viral immunotherapy, thymosin alpha-1 occupies a different role than direct-acting antivirals like tenofovir or entecavir for hepatitis B. The direct antivirals suppress viral replication. Thymosin alpha-1 restores immune competence to clear the virus. The two approaches are complementary, and combination regimens have been studied in chronic hepatitis B with mixed results.

What Comes Next

The PCAC vote in July 2026 will determine whether thymosin alpha-1 returns to legal compounding in the United States. The compound has the strongest combined international approval history and clinical-trial safety database of any peptide on the Category 2 list. Whether that is enough to support Category 1 placement is the central question for the committee. Outside the US, the molecule has been on the market for nearly three decades, with a stable indication set and an evidence base that continues to grow in cancer adjuvant therapy and acute-on-chronic liver failure.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.